Zhitong Finance App News, China Resources Shuanghe (600062.SH) issued an announcement. Recently, Beijing Wanhui Shuanghe Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Drug Registration Certificate” for baritinib tablets issued by the State Drug Administration. Baritinib tablets are suitable for rheumatoid arthritis, alopecia areata, and juvenile idiopathic arthritis.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.